UAB-Led Trial Shines Light on Limitations of Duloxetine for CIPN Prevention

In a landmark clinical trial led by researchers at the University of Alabama at Birmingham (UAB), a commonly prescribed antidepressant has been found ineffective at preventing chemotherapy-induced peripheral neuropathy (CIPN), a debilitating side effect affecting countless cancer patients. The study, known as Alliance A221805, represents the largest randomized, double-blind, placebo-controlled effort to date specifically targeting oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. This research underscores UAB's pivotal role in advancing oncology nursing and cancer survivorship studies within the United States higher education landscape.

Chemotherapy-induced peripheral neuropathy, or CIPN, manifests as numbness, tingling, pain, and weakness primarily in the hands and feet. These symptoms can persist long after treatment ends, severely impacting patients' daily lives—from simple tasks like buttoning a shirt to maintaining balance and avoiding falls. For universities like UAB, with its NCI-designated O'Neal Comprehensive Cancer Center, such investigations are crucial for bridging gaps between clinical practice and patient-centered care.

Understanding the Burden of CIPN in American Cancer Care

CIPN strikes up to 70% of patients receiving neurotoxic chemotherapy shortly after starting treatment, with around 30-40% experiencing chronic symptoms that last years or even a lifetime. In the United States, where over 1.5 million new cancer cases demand chemotherapy annually, this translates to hundreds of thousands grappling with persistent nerve damage. The condition often forces dose reductions or early cessation of life-saving therapy, compromising outcomes while diminishing quality of life through sleep disturbances, mobility issues, and emotional distress.

Oxaliplatin, a platinum-based agent standard in colorectal cancer regimens like FOLFOX, is notorious for triggering acute cold hypersensitivity and chronic sensory deficits. Colorectal cancer, the third most common malignancy in the US, sees over 150,000 diagnoses yearly, making effective prevention strategies a pressing need for institutions training the next generation of oncologists and nurses.

Duloxetine's Journey: Effective for Pain Relief, Not Prevention

Duloxetine, a serotonin-norepinephrine reuptake inhibitor marketed as Cymbalta, has earned American Society of Clinical Oncology (ASCO) endorsement for treating established painful CIPN due to prior trials showing symptom relief. Researchers hypothesized its neuroprotective properties might preempt nerve damage if administered prophylactically from the outset of chemotherapy. UAB's Ellen M. Lavoie Smith, Ph.D., interim associate dean for Research and Scholarship at the School of Nursing, spearheaded the investigation to test this promise.

"Since we know duloxetine is effective at treating painful neuropathy caused by neurotoxic chemotherapy drugs, we wanted to see if the medication could also prevent the side effect from developing in the first place," Smith explained in a UAB release.

Inside the Alliance A221805 Trial: Design and Execution

Conducted across 73 US cancer centers through the National Cancer Institute-funded Alliance for Clinical Trials in Oncology, the phase II trial enrolled 199 adults aged 25+ with stage II-III colorectal cancer, no prior neuropathy, and ECOG performance status 0-2. Participants received standard oxaliplatin (85 mg/m² biweekly for 6-12 cycles or 130 mg/m² triweekly for 4 cycles) alongside randomization to duloxetine 30 mg daily, 60 mg daily, or matching placebo starting day 1 of cycle 1 for 17 weeks.

The primary endpoint—a composite patient-reported outcome using the EORTC QLQ-CIPN20 scale—measured responders (highest sensory score ≤2 on numbness/tingling/pain without OIPN-related withdrawal) at weeks 19-21 post-baseline. Of 143 evaluable patients (71.8%), demographics reflected typical cohorts: mean age 55, 59% male, 81% White.

Results: No Significant Benefit Over Placebo

Responder rates were strikingly similar: 68% placebo, 65.2% duloxetine 30 mg, 66% 60 mg—no statistical differences (ORs ~0.93-1.04, P>0.8). Sensitivity analyses accounting for missing data (due to dropouts or incomplete surveys) confirmed consistency. Cumulative oxaliplatin exposure and dose intensity were comparable across arms, ruling out confounding.

Adherence proved challenging, with only 44-57% achieving ≥75% compliance via pill counts, versus 66% placebo—highlighting real-world barriers like side effects (fatigue 52%, nausea 47%). Grade 3+ adverse events occurred in 30-36% across groups. These findings, detailed in JCO Oncology Practice (March 2026), affirm duloxetine's role post-onset but nix preventive use.

"While duloxetine remains an important option for managing painful chemotherapy-induced neuropathy once it develops, this trial confirms that it should not be used for prevention," Smith noted.

UAB School of Nursing: Pioneering CIPN Research

Ellen Lavoie Smith's trajectory exemplifies UAB's nursing school's prowess in symptom science. A prolific researcher with NCI R01 funding, she directs trials via Alliance, focusing on CIPN mechanisms, assessment, and interventions. Her work spans pediatric CIPN patterns to social determinants influencing severity, positioning UAB as a hub for interprofessional oncology research.

The School of Nursing, with $20.5 million in annual grants—the highest ever—integrates precision health and clinical trials. Collaborations with O'Neal Cancer Center, an NCI-designated powerhouse since 1974, amplify impacts: over 330 faculty drive breakthroughs in immunotherapy, nutrition, and survivorship.

Patient Impacts: QoL, Falls, and Economic Toll

CIPN erodes health-related quality of life (HRQoL), correlating with anxiety, depression, and activity limitations. US survivors report falls (20-30% increased risk), sleep disruption, and employment challenges—costing billions in healthcare and lost productivity. A study pegged chronic painful CIPN at 41% prevalence among affected patients, disproportionately burdening platinum/taxane recipients.

For colorectal patients, persistent symptoms hinder recovery, underscoring universities' role in fostering supportive care innovations.

Broadening U.S. University Efforts Against CIPN

UAB's trial joins a chorus: cryotherapy, exercise, and neuromodulators show mixed promise. Recent advances include IRE1α inhibitors targeting immune stress and TAK1 blockade. Institutions like VCU Massey and Wake Forest probe mechanisms, while Mayo and MD Anderson test cryocompression. Nursing programs nationwide emphasize CIPN education, training clinicians for holistic management.

Read the full study in JCO Oncology Practice.

Stakeholder Perspectives: Oncologists, Nurses, Survivors

Oncologists value the trial's rigor, noting high placebo responses (68%) signal psychological factors or assessment timing. Nurses advocate patient education on risks, while survivors via forums like Cancer Survivors Network emphasize non-pharmacologic aids: acupuncture, yoga, balanced nutrition.

Future Outlook: Biomarkers and Novel Therapies

Smith calls for biomarker-driven trials (e.g., neurofilament light chain) and longer follow-up. Emerging: PC-SOD antioxidants (phase III), CBD pilots, Paxman cryocompression. UAB's pipeline promises more, leveraging AI for prediction models.

Explore UAB's announcement for deeper insights.

UAB's Commitment to Cancer Survivorship

As US universities grapple with rising cancer incidence (1.9M cases projected 2026), UAB exemplifies translational excellence. Its nursing-led initiatives train future leaders, ensuring evidence guides care.

Photo by Karl Solano on Unsplash